Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy

被引:0
作者
Shigematsu, Hideo [1 ]
Takaya, Momoko [1 ]
Suzuki, Kanako [1 ]
Fujimoto, Mutsumi [1 ]
Ikejiri, Haruka [1 ]
Amioka, Ai [1 ]
Hiraoka, Emiko [1 ]
Sasada, Shinsuke [1 ]
Arihiro, Koji [2 ]
Okada, Morihito [1 ]
机构
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, 1-2-3-Kasumi,Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ Hosp, Dept Anat Pathol, Hiroshima 7348551, Japan
关键词
Breast cancer; Neoadjuvant chemotherapy; YpT0; YpN0; Axillary surgery omission; MULTICENTER; BIOPSY;
D O I
10.1007/s10549-025-07697-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeAxillary staging is commonly performed in patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NACT), regardless of pathological complete response (pCR). Recent evidence has suggested that ypT0 correlates with ypN0 and favorable prognosis, potentially supporting the omission of axillary staging in such cases. This study aimed to evaluate ypT0 as a predictive factor for ypN status and its prognostic significance in cN+ breast cancer treated with NACT.MethodsThis retrospective study included 302 patients with cN+ breast cancer treated with NACT at Hiroshima University Hospital between 2006 and 2022. Patients were categorized into non-pCR, ypTis, or ypT0 based on ypT status. Associations between breast pCR, ypN status, recurrence-free survival (RFS), and overall survival (OS) were analyzed.ResultsAmong 302 patients (non-pCR, 74.2%; ypTis, 8.9%; ypT0, 16.9%), the ypN+ rates were 63.3%, 15.2%, and 3.9%, respectively. Logistic regression revealed significant associations among ypT0, ypTis, and ypN0. The five-year RFS and OS rates were 78.6% and 85.2% (non-pCR), 83.8% and 95.5% (ypTis), and 98.0% and 100.0% (ypT0), respectively. Cox regression identified ypT0, but not ypTis, as a significant prognostic factor for both RFS and OS.ConclusionypT0 status was associated with a low risk of ypN+ and favorable clinical outcomes in cN+ breast cancer, suggesting the potential feasibility of omitting axillary surgery in select patients.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 29 条
  • [1] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) : 1346 - +
  • [2] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
    Amin, Mahul B.
    Greene, Frederick L.
    Edge, Stephen B.
    Compton, Carolyn C.
    Gershenwald, Jeffrey E.
    Brookland, Robert K.
    Meyer, Laura
    Gress, Donna M.
    Byrd, David R.
    Winchester, David P.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
  • [3] Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy
    Barron, Alison U.
    Hoskin, Tanya L.
    Day, Courtney N.
    Hwang, E. Shelley
    Kuerer, Henry M.
    Boughey, Judy C.
    [J]. JAMA SURGERY, 2018, 153 (12) : 1120 - 1126
  • [4] Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
    Boileau, Jean-Francois
    Poirier, Brigitte
    Basik, Mark
    Holloway, Claire M. B.
    Gaboury, Louis
    Sideris, Lucas
    Meterissian, Sarkis
    Arnaout, Angel
    Brackstone, Muriel
    McCready, David R.
    Karp, Stephen E.
    Trop, Isabelle
    Lisbona, Andre
    Wright, Frances C.
    Younan, Rami J.
    Provencher, Louise
    Patocskai, Erica
    Omeroglu, Atilla
    Robidoux, Andre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 258 - U150
  • [5] Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
    Bossuyt, V.
    Provenzano, E.
    Symmans, W. F.
    Boughey, J. C.
    Coles, C.
    Curigliano, G.
    Dixon, J. M.
    Esserman, L. J.
    Fastner, G.
    Kuehn, T.
    Peintinger, F.
    von Minckwitz, G.
    White, J.
    Yang, W.
    Badve, S.
    Denkert, C.
    MacGrogan, G.
    Penault-Llorca, F.
    Viale, G.
    Cameron, D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (07) : 1280 - 1291
  • [6] Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
    Boughey, Judy C.
    Suman, Vera J.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Leitch, A. Marilyn
    Kuerer, Henry M.
    Bowling, Monet
    Flippo-Morton, Teresa S.
    Byrd, David R.
    Ollila, David W.
    Julian, Thomas B.
    McLaughlin, Sarah A.
    McCall, Linda
    Symmans, W. Fraser
    Le-Petross, Huong T.
    Haffty, Bruce G.
    Buchholz, Thomas A.
    Nelson, Heidi
    Hunt, Kelly K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14): : 1455 - 1461
  • [7] Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China
    Chen, Rui
    Li, Shuo
    Li, Yan
    Zhu, Qiannan
    Shi, Xiaoqing
    Xu, Lu
    Xu, Yinggang
    Zhang, Weiwei
    Huang, Xiaofeng
    Wang, Jue
    Zha, Xiaoming
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3495 - 3501
  • [8] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
  • [9] Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
    Curigliano, G.
    Burstein, H. J.
    Gnant, M.
    Loibl, S.
    Cameron, D.
    Regan, M. M.
    Denkert, C.
    Poortmans, P.
    Weber, W. P.
    Thurlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 (11) : 970 - 986
  • [10] Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
    de Boniface, Jana
    Filtenborg Tvedskov, Tove
    Ryden, Lisa
    Szulkin, Robert
    Reimer, Toralf
    Kuehn, Thorsten
    Kontos, Michalis
    Gentilini, Oreste D.
    Olofsson Bagge, Roger
    Sund, Malin
    Lundstedt, Dan
    Appelgren, Matilda
    Ahlgren, Johan
    Norenstedt, Sophie
    Celebioglu, Fuat
    Sackey, Helena
    Scheel Andersen, Inge
    Hoyer, Ute
    Nyman, Per F.
    Vikhe Patil, Eva
    Wieslander, Elinore
    Dahl Nissen, Henrik
    Alkner, Sara
    Andersson, Yvette
    Offersen, Birgitte V.
    Bergkvist, Leif
    Frisell, Jan
    Christiansen, Peer
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (13) : 1163 - 1175